accession therapeutics

Creating the ideal immunotherapy

Dr Dave Cole
dave.cole@accessiontherapeutics.com
Head of Research, Accession Executive Team

Accession Executive Team - experienced from research to clinic

Prof Bent Jakobsen
CEO and Founder
25 years as an Immunotherapy pioneer. Scientific Founder of two unicorns: Adaptimmune Ltd & Immunocore Ltd

Prof Alan Parker
Chief Scientific Officer, Trocept Therapeutics

Dr Dave Cole
Head of Research

Dr Jez Gerry
Head of Preclinical Development

Andy Johnson
Head of CMC

Dr David Krige
Head of Translational sciences

Prof Hardev Pandha
Head of Clinical

Translated >10 innovative research projects from PoC to regulatory submissions and clinical trials

Our in-depth bios can be found at: www.accessiontherapeutics.com/our-team

Stephanie Bewick
CBO

Ranjeet Babbra
Head of Quality & Strategy

Nick Cross
CFO and Chairman

Pipeline: parallel development of fully differentiated clinical candidates



Cancers have heterogenous expression of different antigens

Problem 1: cancers are highly heterogenous containing 1000s of clones



1000s of different cancer clones

Accession has developed a unique tumor -localizing viral platform for I.V. delivery

trocept

trocept first-in-class I.V. delivery of tumor-disrupting drugs - overcoming the limitations of existing viral platforms



Unique

Does not target healthy cells



Directed

Cancer specific targeting



Potent

Amplifies broad tumor activity

Wildtype Ad5 infects normal cells



Wildtype Ad5

Infection of healthy tissue



Wildtype Ad5 infects normal cells



Wildtype Ad5

Infection of healthy tissue



Green = virus in liver & spleen

Wildtype Ad5 infects normal cells, mostly the liver, reducing viral bioavailability for tumors

trocept is engineered (Mods.1-3) not to infect normal cells



Wildtype Ad5

Infection of healthy tissue



Green = virus in liver & spleen

Wildtype Ad5 infects normal cells, mostly the liver, reducing viral bioavailability for tumors



trocept

No infection of healthy tissue



trocept is engineered (Mods.1-3) not to infect normal cells



Wildtype Ad5

Infection of healthy tissue



Green = virus in liver & spleen

Wildtype Ad5 infects normal cells, mostly the liver, reducing viral bioavailability for tumors



trocept

No infection of healthy tissue



No Trocept in liver or spleen

Trocept has been engineered not to target healthy cells (unique feature)

Trocept avoids elimination by the liver (chief limitation of other viral therapies)

Wildtype Ad5 infects normal cells and provides limited protection



Wildtype Ad5

Infection of healthy tissue





All mice die

Wildtype Ad5 infects normal cells, mostly the liver, reducing tumor efficacy

trocept localizes to tumors (Mod.4) achieving 100% survival



Wildtype Ad5

Infection of healthy tissue





Wildtype Ad5 infects normal cells, mostly the liver, reducing tumor efficacy



Only infects tumor cells





Trocept has been engineered (Mod 4) to bind to αvβ6 integrin

Enables efficient and specific viral cell entry into tumor cells

trocept is engineered to bind αvβ6 integrin, a cancer-specific marker highly expressed on several indications

Carcinoma type	Incidence per year	Cancer deaths rank	5 year survival %	Approved ICI ORR (%)	% positive tumors
Head & Neck	66,920	15th	~60	~14	100
Pancreas	62,210	3rd	11	0	100
Gastric	26,380	14th	32	~14	84
Ovarian	19,880	11th	35	~9%	100
NSCLC	238,340	1st	23	~40	87
Colon	153,020	2nd	65	~13	86

USA figures from cancer.net

In-house IHC

trocept one: *in tumor* anti-PDL1 immune checkpoint inhibitor expression via I.V. delivery



accession therapeutics

Systemically delivered anti-PDL1 ICIs have overall limited efficacy



trocept *in tumor anti-PDL1* ICI expression should enhance potency, reduce toxicity and generate novel IP



trocept turns cancer cells into ICI drug factories

Generation of functional ICIs by **trocept one** infected cancer cells

Therapeutic drug release





Anti-tumor immune response





High yields of ICIs generated

ICIs are fully functional in cell assays

trocept one: anti-PDL1 ICI tumor delivery FIH 1H 2024

Trocept one: *in tumor* delivery of anti-PDL1 ICIs

- Virally induced immunity turns cold tumors hot
- Enables high anti-PDL1 concentration only in the tumor
- Could improve response rates and generate new IP in a highly attractive therapeutic area
- Rapid development into the clinic (1H 2024)

Where are we differentiated?

Trocept platform enables expression of unique agents only in the tumor that would be too toxic/broad in reactivity to be administered in any other way



accession therapeutics

Trocept enables tumor-localized expression of drugs that would be too toxic for systemic delivery

Problem 1: cancers are highly heterogenous containing 1000s of clones

Solution 1: express broad and potent drugs that target all tumor cells



trocept three/four : expression of universal bispecifics ***only*** in the tumor

accession therapeutics

Accession has developed a universal bispecific that targets all cancer cells to address tumor diversity…



Conventional bispecifics: The tumor is edited and develops therapy resistance

Accession has developed a universal bispecific that targets all cancer cells to address tumor diversity…



Solution: **universal bispecifics** that targets all tumor cells

Trocept enables tumor-localized expression of universal bispecifics to target all cells in the cancer



Partnerships and collaborations



✅ Accession is interested partnerships on its programs

✅ Collaborations on its Trocept platform: could deliver partner nominated transgenes